247 related articles for article (PubMed ID: 22824079)
1. A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II).
Tsuburaya A; Morita S; Kodera Y; Kobayashi M; Shitara K; Yamaguchi K; Yoshikawa T; Yoshida K; Yoshino S; Sakamoto J
BMC Cancer; 2012 Jul; 12():307. PubMed ID: 22824079
[TBL] [Abstract][Full Text] [Related]
2. A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II).
Nishikawa K; Tsuburaya A; Yoshikawa T; Kobayashi M; Kawada J; Fukushima R; Matsui T; Tanabe K; Yamaguchi K; Yoshino S; Takahashi M; Hirabayashi N; Sato S; Nemoto H; Rino Y; Nakajima J; Aoyama T; Miyagi Y; Oriuchi N; Yamaguchi K; Miyashita Y; Morita S; Sakamoto J
Eur J Cancer; 2018 Sep; 101():220-228. PubMed ID: 30096702
[TBL] [Abstract][Full Text] [Related]
3. A retrospective comparison of S-1 plus cisplatin and capecitabine plus cisplatin for patients with advanced or recurrent gastric cancer.
Shitara K; Sawaki A; Matsuo K; Kondo C; Takahari D; Ura T; Tajika M; Niwa Y; Muro K
Int J Clin Oncol; 2013 Jun; 18(3):539-46. PubMed ID: 22552360
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial.
Nishikawa K; Tsuburaya A; Yoshikawa T; Takahashi M; Tanabe K; Yamaguchi K; Yoshino S; Namikawa T; Aoyama T; Rino Y; Kawada J; Tsuji A; Taira K; Kimura Y; Kodera Y; Hirashima Y; Yabusaki H; Hirabayashi N; Fujitani K; Miyashita Y; Morita S; Sakamoto J
Gastric Cancer; 2018 Sep; 21(5):811-818. PubMed ID: 29488122
[TBL] [Abstract][Full Text] [Related]
5. Comparison of S-1-cisplatin every 5 weeks with capecitabine-cisplatin every 3 weeks for HER2-negative gastric cancer (recurrent after S-1 adjuvant therapy or chemotherapy-naïve advanced): pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials.
Kawakami H; Fujitani K; Matsuyama J; Akamaru Y; Tamura S; Endo S; Kimura Y; Makari Y; Tamura T; Sugimoto N; Sakai D; Tsujinaka T; Goto M; Kurokawa Y; Shimokawa T; Satoh T;
Int J Clin Oncol; 2020 Sep; 25(9):1635-1643. PubMed ID: 32494981
[TBL] [Abstract][Full Text] [Related]
6. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.
Lee J; Lim DH; Kim S; Park SH; Park JO; Park YS; Lim HY; Choi MG; Sohn TS; Noh JH; Bae JM; Ahn YC; Sohn I; Jung SH; Park CK; Kim KM; Kang WK
J Clin Oncol; 2012 Jan; 30(3):268-73. PubMed ID: 22184384
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4).
Boku N; Ryu MH; Kato K; Chung HC; Minashi K; Lee KW; Cho H; Kang WK; Komatsu Y; Tsuda M; Yamaguchi K; Hara H; Fumita S; Azuma M; Chen LT; Kang YK
Ann Oncol; 2019 Feb; 30(2):250-258. PubMed ID: 30566590
[TBL] [Abstract][Full Text] [Related]
8. Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
Bilici A; Selcukbiricik F; Demir N; Oven Ustaalioglu BB; Dikilitas M; Yildiz O
Asian Pac J Cancer Prev; 2014; 15(20):8661-6. PubMed ID: 25374186
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer.
Satoh T; Yamada Y; Muro K; Hayashi H; Shimada Y; Takahari D; Taku K; Nakajima TE; Shi X; Brown KH; Boku N
Cancer Chemother Pharmacol; 2012 Feb; 69(2):439-46. PubMed ID: 21853311
[TBL] [Abstract][Full Text] [Related]
10. A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine.
Lee KW; Kim BJ; Kim MJ; Han HS; Kim JW; Park YI; Park SR
Cancer Res Treat; 2017 Jul; 49(3):706-716. PubMed ID: 27764906
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of cetuximab plus S-1/cisplatin therapy in Japanese patients with advanced gastric cancer.
Yamaguchi K; Fuse N; Komatsu Y; Fujii H; Hironaka S; Omuro Y; Muro K; Yasui H; Ueda S; Nishina T; Watanabe M; Ohtsu A
Jpn J Clin Oncol; 2021 May; 51(6):879-885. PubMed ID: 33561262
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study.
Yamaguchi K; Sawaki A; Doi T; Satoh T; Yamada Y; Omuro Y; Nishina T; Boku N; Chin K; Hamamoto Y; Takiuchi H; Komatsu Y; Saji S; Koizumi W; Miyata Y; Sato A; Baba E; Tamura T; Abe T; Ohtsu A
Gastric Cancer; 2013 Apr; 16(2):175-82. PubMed ID: 22782463
[TBL] [Abstract][Full Text] [Related]
13. Randomized, Open-Label Phase II Study Comparing Capecitabine-Cisplatin Every 3 Weeks with S-1-Cisplatin Every 5 Weeks in Chemotherapy-Naïve Patients with HER2-Negative Advanced Gastric Cancer: OGSG1105, HERBIS-4A Trial.
Kawakami H; Takeno A; Endo S; Makari Y; Kawada J; Taniguchi H; Tamura S; Sugimoto N; Kimura Y; Tamura T; Fujitani K; Sakai D; Shimokawa T; Kurokawa Y; Satoh T
Oncologist; 2018 Dec; 23(12):1411-e147. PubMed ID: 30115736
[TBL] [Abstract][Full Text] [Related]
14. [A case of gastric cancer showing response to first-line XP regimen after lymph node recurrence during the administration of S-1 as postoperative adjuvant chemotherapy].
Mihara K; Yamashiro N; Nishiya S; Kemmochi T; Ito Y; Egawa T; Nagashima A
Gan To Kagaku Ryoho; 2014 Nov; 41(12):2358-60. PubMed ID: 25731522
[TBL] [Abstract][Full Text] [Related]
15. Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study.
Kim ST; Kang JH; Lee J; Park SH; Park JO; Park YS; Lim HY; Hwang IG; Lee SC; Park KW; Lee HR; Kang WK
Eur J Cancer; 2014 Nov; 50(16):2822-30. PubMed ID: 25218337
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.
Kim GM; Jeung HC; Rha SY; Kim HS; Jung I; Nam BH; Lee KH; Chung HC
Eur J Cancer; 2012 Mar; 48(4):518-26. PubMed ID: 22243774
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of three randomized trials of capecitabine plus cisplatin (XP) versus S-1 plus cisplatin (SP) as first-line treatment for advanced gastric cancer.
Nishikawa K; Kawakami H; Shimokawa T; Fujitani K; Tamura S; Endo S; Kobayashi M; Kawada J; Kurokawa Y; Tsuburaya A; Yoshikawa T; Sakamoto J; Satoh T;
Int J Clin Oncol; 2023 Nov; 28(11):1501-1510. PubMed ID: 37634209
[TBL] [Abstract][Full Text] [Related]
18. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin in Chinese patients with advanced and metastatic gastric cancer: Re-analysis of efficacy and safety data from the ML17032 phase III clinical trial.
Chen J; Xiong J; Wang J; Zheng L; Gao Y; Guan Z
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e310-e316. PubMed ID: 29372626
[TBL] [Abstract][Full Text] [Related]
19. Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study.
Seol YM; Song MK; Choi YJ; Kim GH; Shin HJ; Song GA; Chung JS; Cho GJ
Jpn J Clin Oncol; 2009 Jan; 39(1):43-8. PubMed ID: 18997184
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]